Results 171 to 180 of about 155,549 (248)

The EGFR regulates bacterial clearance in cystic fibrosis airway neutrophils. [PDF]

J Clin Invest
Rasmussen LW, Luthra D, Moncada-Giraldo D, Lewis C, Soto-Vazquez YM, Li Z, Hu B, Dobosh BS, Stacks DA, Koff JL, Gaggar A, Tirouvanziam R, Margaroli C.   +12 more
europepmc   +1 more source

Exploring the Correlation Between Surgical Depth and Postoperative Voice Rest Duration in a Rabbit Phonomicrosurgery Model

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective The optimal duration of voice rest after phonomicrosurgery remains a subject of debate, as clinical studies on its effect on vocal fold wound healing have yielded conflicting results, and a controlled animal model for investigating voice rest is currently unavailable. This study aimed to determine the optimal postoperative voice rest
Lin‐Lin Lan, Qiu‐Rong Yang, Pei‐Yun Zhuang   +2 more
wiley   +1 more source

Cystic fibrosis and sickle cell disease associated with nonadministration of VTE prophylaxis in hospitalized adults. [PDF]

Blood Adv
Caparon K, Lankiewicz MJ, Crow J, Yui JC, Lindsley J, Lau BD, Streiff MB, Naik RP, Lanzkron S, Pecker LH, Kraus P, Haut ER, Wang J, Dane KE.   +13 more
europepmc   +1 more source

Kidney Failure in Persons With Cystic Fibrosis. [PDF]

Kidney Med
Stevanovic M, MacKenzie TA, Zimmerman AM, Graber ML.   +3 more
europepmc   +1 more source

Red blood cell deformability as a mechanobiological marker of CFTR dysfunction in cystic fibrosis. [PDF]

iScience
Pero E, Tomaiuolo G, Villella VR, Esposito S, Vetrone MA, Panarelli A, Castaldo A, Sepe A, Andolfo I, Tosco A, Castaldo G, Raia V, Guido S.   +12 more
europepmc   +1 more source

Examining the role of freebase nicotine in the harm reduction potential of oral nicotine pouches versus moist snuff: A randomized crossover trial

Addiction, EarlyView.
Abstract Background and aims Oral nicotine pouches (ONPs) contain varying proportions of freebase nicotine (FBN), with higher FBN expected to increase nicotine delivery across the oral mucosa. Because ONPs contain fewer toxicants than moist snuff and may serve as a reduced harm alternative for smokeless tobacco, we compared how the FBN in ONPs affects ...
Brittney Keller‐Hamilton, Hayley Curran, Leanne Atkinson, Sriya Suraapaneni, Alice Hinton, Kirsten Chrzan, Darren Mays, Ahmad El‐Hellani, Clark W. Wilson, Marielle C. Brinkman, Theodore L. Wagener   +10 more
wiley   +1 more source

Physiologically Based Pharmacokinetic Modeling of Elexacaftor/Tezacaftor/Ivacaftor in Infants With Cystic Fibrosis. [PDF]

CPT Pharmacometrics Syst Pharmacol
Truong NH, Benaboud S, Bouazza N, Deneuville E, Mornand A, Reix P, Ribault M, Burgel PR, Froelicher-Bournaud L, Rouillon S, Sanoufi MR, Lui G, Urien S, Tréluyer JM, Sermet-Gaudelus I, Foissac F, Modul‐CF study group.   +16 more
europepmc   +1 more source

The prevalence of cannabidiol (CBD) use in North America and Europe: A meta‐analysis

Addiction, EarlyView.
Abstract Background and aims The global cannabidiol (CBD) market has expanded in recent years. Several studies suggest CBD use, whether for medical or recreational purposes, is on the rise; however, no systematic assessments of its prevalence have been conducted so far. This meta‐analysis aimed to estimate the prevalence of CBD use in North America and
Sara Weidberg, Clara Iza‐Fernández, Layla Alemán‐Moussa, Andrea Krotter, Alba González‐Roz   +4 more
wiley   +1 more source

Evaluation of the Need for Comprehensive Care for Patients with Cystic Fibrosis. [PDF]

J Am Board Fam Med
Kolk K, Hornick DB, Pena T, Wright BA.
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source